Full-Time

Quality Assurance Analyst 2

Posted on 9/9/2026

Biolinq

Biolinq

51-200 employees

Biowearable biosensor platform for metabolic health

Compensation Overview

$80k - $95k/yr

+ Annual performance bonus + Incentive compensation

San Diego, CA, USA

In Person

Bachelor's, Associate's

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Quality Assurance (QA)

Get referred to Biolinq

See people who can refer or advise you

Requirements
  • An Associate degree and four years of experience, a Bachelor's degree preferred, or an equivalent combination of experience and education.
  • At least three years of experience in a medical device, biotechnology, pharmaceutical, Food and Drug Administration-regulated, or International Organization for Standardization-regulated industry is required.
  • Experience with electronic and paper-based quality management systems.
  • Critical thinking skills.
  • Ability to interface and communicate with multiple departments and work in a fast-paced, multidisciplinary environment.
  • Ability to manage multiple tasks and communicate clearly with the team, with strong written and verbal communication skills.
Responsibilities
  • Process change orders in an electronic quality management system, review them for compliance with work instructions, and work with submitters to revise them as required.
  • Create and assign training lessons in an electronic quality management system, attach the correct documents, create course quizzes as applicable, and assign lessons to appropriate employees.
  • Organize, collect, and file paper records associated with manufacturing and Quality.
  • Communicate with multiple teams to prioritize change orders.
  • Control the assignment and collection of logbooks.
  • Assign manufacturing device history record and document numbers.
  • Conduct in-person employee training sessions on various topics.
  • Conduct employee onboarding training on Quality-related topics.
  • Create or revise procedures or work instructions in areas of focus.
  • Conduct assigned investigations for nonconformance report or corrective and preventive action events.
  • Contribute to the Supplier Management process by updating ISO certificates and the supplier spreadsheet.
  • Pull reports for departmental metrics.
  • Assist the Quality team in hosting external and customer audits.
Desired Qualifications
  • A Bachelor's degree.
  • A biological, chemistry, quality, or engineering discipline.
  • At least three years of experience in Quality Document Control.
  • Medical device, biotechnology, or pharmaceutical experience; MDSAP or MDR experience is preferred.
  • Experience with MasterControl.
  • Experience with internal and external audit activities.

Biolinq develops a biowearable platform with tiny under-skin sensors that monitor metabolic health, including glucose, by sensing multiple analytes. The sensors continuously collect data below the skin and transmit to an app or clinician for insights and personalized medicine. It differentiates by being a small, under-skin, multi-analyte system backed by university bioengineering research, not external wearables or single markers. Its goal is to gain regulatory approval and bring scalable, continuous metabolic health monitoring to patients.

Company Size

51-200

Company Stage

Series C

Total Funding

$316.4M

Headquarters

San Diego, California

Founded

2012

Get referred to Biolinq

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biolinq raised $100 million in April 2025, funding launch and regulatory execution.
  • ClinicalTrials.gov updated February 20, 2026, showing active studies supporting commercial marketing applications.
  • Biolinq posted manufacturing and software jobs in July 2026, indicating launch readiness.

What critics are saying

  • FDA labels Shine only for non-insulin type 2 diabetes, shrinking the addressable market.
  • Abbott and Dexcom dominate CGMs, forcing Biolinq into expensive, evidence-heavy differentiation.
  • Pilot manufacturing hiring in July 2026 signals scale-up risk before broad commercialization.

What makes Biolinq unique

  • Biolinq Shine won FDA De Novo on September 23, 2025, defining a new category.
  • Its intradermal microsensor sits shallower than filament CGMs, reducing insertion pain.
  • The patch shows color-coded glucose ranges without a paired smartphone, simplifying use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Holidays

Paid Vacation

PTO

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
Yahoo Finance
Feb 2nd, 2026
Biolinq CEO predicts smart patches will dominate wearables after $100M Series C

Smart patches could become the next major wearables category after smartwatches and rings, according to Richard Yang, CEO of diabetes biosensor company Biolinq. Unlike watches that track digital biomarkers, smart patches monitor biomarkers linked to the body's internal chemistry. Biolinq raised $100 million in a Series C round in April 2025, bringing total funding to around $300 million. The company secured FDA de novo classification for its Shine biosensor in September 2025, making it the first needle-free continuous glucose monitoring device in the US market. The device uses microneedle arrays that only penetrate the skin's top layer. Yang says the consumer health domain is "hungry" for such technology. Biolinq plans to expand beyond diabetes monitoring, with future applications potentially tracking multiple health metrics simultaneously through semiconductor-based biosensor chips.

Live Forever Club CIC
May 5th, 2025
Biolinq raises $100M for glucose monitor

Biolinq, a California-based health tech company, has secured $100 million in Series C funding to advance its needle-free glucose monitor for Type 2 diabetes. The coin-sized patch uses electrochemical sensors to track glucose, lactate, and ketones without penetrating deeply into tissue. It also monitors sleep and activity, providing real-time feedback. The funding, led by Alpha Wave Ventures, will support development, U.S. regulatory submissions, and commercial rollout.

Venture Capital Investor
Apr 29th, 2025
Biolinq Secures $100 Million Series C

Biolinq, a maker of a biowearable glucose sensor platform, has closed a $100 million Series C financing round led by Alpha Wave Ventures, with participation from existing investors including RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.

FinSMEs
Apr 23rd, 2025
Biolinq Closes $100M Series C Financing

Biolinq, a San Diego, CA-based healthcare technology company providing precision multi-analyte biosensors, raised $100M in Series C funding.

Medical Device Network
Apr 23rd, 2025
Biolinq raises $100m to support US launch of intradermal glucose sensor

Biolinq has secured $100m in a Series C funding round to support the regulatory approval process in the US as it aims to launch its autonomous intradermal glucose sensor to the market.